Expand NTLA Menu
NTLA MENU

NTLA Latest Press Releases

-- January 28, 2026 --

Cutting DNA, Cutting Edge: Companies Using CRISPR and Other Gene Editing Technologies to Rewrite the Future of Industry and Medicine Globe Newswire 8:05 AM

-- January 27, 2026 --

Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE-2 Phase 3 Clinical Trial in ATTRv-PN Globe Newswire 8:00 AM

-- January 7, 2026 --

Intellia Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference Globe Newswire 7:30 AM

-- January 2, 2026 --

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:01 PM

-- December 5, 2025 --

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:01 PM

-- November 18, 2025 --

Longevity-Focused Health Fueling U.S. Anti-Aging Products Market Projected to Reach $27 Billion By 2033 Globe Newswire 8:45 AM

-- November 10, 2025 --

Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy Globe Newswire 3:17 PM

-- November 8, 2025 --

Intellia Therapeutics Presents Positive Pooled Phase 1/2 Data of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Globe Newswire 5:13 PM

-- November 6, 2025 --

Intellia Therapeutics Announces Third Quarter 2025 Financial Results and Recent Updates Globe Newswire 4:00 PM

-- October 27, 2025 --

Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z) Globe Newswire 7:30 AM

-- October 3, 2025 --

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:01 PM

-- September 25, 2025 --

Intellia Therapeutics Announces Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran (nex-z) in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy Globe Newswire 9:52 AM

-- September 22, 2025 --

Intellia Therapeutics to Present Longer-Term Data from the Ongoing Phase 1 Clinical Trial of Nexiguran Ziclumeran (nex-z) for the Treatment of Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy Globe Newswire 7:30 AM

-- September 18, 2025 --

Intellia Therapeutics Completes Enrollment in the Global Phase 3 HAELO Study of Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema Globe Newswire 7:30 AM

-- August 30, 2025 --

NTLA, DKNG: Cathie Wood Bets Millions on Biotech, Continues Dumping DraftKings Stock TipRanks 2:36 AM
Market Data Delayed 15 Minutes